Thank you for your comment, but I think it’s important to address some of the core issues that are causing frustration among long-term investors. It’s not just “emotional meltdowns” but genuine concerns about management practices and the direction of the company.Lesley alluding to milestones and breakthroughs that don’t materialize has eroded trust. These repeated instances of overpromising and underdelivering make it difficult for shareholders to remain optimistic or even engaged. A track record like this doesn’t inspire confidence in leadership, regardless of the scientific potential.As for Paul Hopper, the optics of loaning out shares he didn’t personally fund are troubling. It’s one thing to see leadership invest their own resources and align their interests with shareholders. It’s another to watch these moves that feel disconnected from the risk we, as investors, are bearing.Directors' exorbitant wages also stand out as a red flag. When the company hasn’t delivered on its promises, and investors are absorbing the mental and financial toll of staying the course, it’s disheartening to see management compensated so generously. It feels misaligned with the struggles shareholders endure.Capital raises, while a necessary tool, have felt increasingly predatory. Shareholders are left diluted without much clarity on where the funds are going and why management hasn’t been able to secure better terms or manage resources more effectively. It adds to the growing sentiment that management’s interests don’t align with those of investors.Finally, Yuman Fong may indeed be a brilliant mind and advocate for the science, but management’s handling of timelines, communication, and finances overshadows even the most exciting developments. For many, the loss of trust in the people steering the ship outweighs faith in the science.These concerns aren’t about having “emotional meltdowns.” They’re legitimate frustrations from people who’ve made significant sacrifices to support a company they once believed in. Rebuilding trust with investors starts with management addressing these issues transparently and demonstrating alignment with shareholder interests.
- Forums
- ASX - By Stock
- IMU
- Media Thread
IMU
imugene limited
Add to My Watchlist
0.00%
!
1.1¢

Media Thread, page-16383
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
1.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $82.13M |
Open | High | Low | Value | Volume |
1.1¢ | 1.2¢ | 1.1¢ | $338.0K | 30.69M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
15 | 3480808 | 1.1¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.2¢ | 10994115 | 28 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
15 | 3480808 | 0.011 |
107 | 27410672 | 0.010 |
35 | 16158780 | 0.009 |
14 | 4310247 | 0.008 |
7 | 3365713 | 0.007 |
Price($) | Vol. | No. |
---|---|---|
0.012 | 10994115 | 28 |
0.013 | 7916193 | 26 |
0.014 | 8302051 | 33 |
0.015 | 8094214 | 28 |
0.016 | 6615871 | 27 |
Last trade - 16.10pm 26/06/2025 (20 minute delay) ? |
Featured News
IMU (ASX) Chart |
The Watchlist
PTX
PRESCIENT THERAPEUTICS LIMITED
James McDonnell, CEO
James McDonnell
CEO
Previous Video
Next Video
SPONSORED BY The Market Online